App-Quantinova.ai

Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs).

Linda Wu - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.

Julien Edeline - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Tislelizumab

Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01.

Milind M. Javle - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

A retrospective single centre study exploring the efficacy of sequential tyrosine kinase inhibitors (TKI) in patients with hepatocellular cancer.

Catherine Roberts - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

L-Tyrosine

Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy.

Constance D'abrigeon - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Advanced biliary tract carcinoma

Gemcitabine

A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).

Markus Peck-Radosavljevic - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Lenvatinib

Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): The diagnostic process of GEP-NETs in Australia, Canada, China, France, Germany, the United Kingdom, and the United States of America.

Mark McDonnell - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

N/A

Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).

Pascal Hammel - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Fluorouracil

Liquid biopsy for diagnosis in patients with suspected pancreatic and biliary tract cancers: PREVAIL ctDNA pilot trial.

Justin Mencel - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

Hypofractionated radiotherapy to the pancreas: U.K. experience.

Suliana Teoh - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Cancer Commons’ virtual tumor board program: A patient-centric advisory panel and real-world data registry.

Lola Rahib - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Gemcitabine

Health outcomes of gBRCA testing strategies for metastatic pancreatic cancer patients.

Lin Fan - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Metastatic pancreatic adenocarcinoma

Olaparib

Efficacy of MDX-124, a novel anti-annexin-A1 antibody, in preclinical models of pancreatic cancer.

Fiona C. Dempsey - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Metastatic pancreatic adenocarcinoma

MDX-001

Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).

Natalie Ngoi - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

methionine

High-plex proteomic prognostic marker discovery for patients with pancreatic cancer adenocarcinoma using digital spatial profiling.

Nigel Balfour Jamieson - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02).

Funda Meric-Bernstam - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Trastuzumab

Melanin nanoparticles for safe and effective iron chelation therapy for Beta-thalassemia during pregnancy

Nahla Bakhamis - Society for Maternal-Fetal Medicine (SMFM) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Beta-thalassemia

Phenazone

Early prediction of spontaneous preterm birth in a high-risk population using cfRNA profiling

Joan Camunas-Soler - Society for Maternal-Fetal Medicine (SMFM) , 2022

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Spontaneous preterm delivery

N/A

Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.

Shirin Ardeshirrouhanifard - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Testicular cancer

Cisplatin

Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

Thierry Andre - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Pembrolizumab

Filters

45280 Abstracts